Inscripta's CASE STUDY

Imagine a world where manipulating DNA is as straightforward to researchers as editing a document with word processing software. At Inscripta, we think it’s possible. Inscripta, a revolutionary biotechnology company, has not only envisioned such a future but has also engineered the tools to make it a reality. Founded in 2015, Inscripta is headquartered in Boulder, Colorado, and has emerged as a game-changer in the realm of genomic research with the Onyx™, the world's first scalable platform for benchtop Digital Genome Engineering. In this case study, we delve into Inscripta's journey to revolutionize biotechnology and embed precision genome editing in laboratories worldwide.

The Genesis of Inscripta

Founded on the principles of innovation and accessibility, Inscripta aimed to democratize genome editing, taking it from the realms of high-stakes laboratories into local research settings. Inscripta’s flagship product, the Onyx™, allows scientists to edit genomes with unparalleled precision, speed, and efficiency. Our mission has always been to empower researchers with tools that unlock the complete potential of genome engineering. The Onyx™ platform addresses a critical need in the scientific community: simplifying the complex process of gene editing. According to BioPharma Dive, "Speed in gene editing is crucial, and Inscripta’s technology allows for rapid iteration, bringing new findings to light in weeks rather than months." This platform is not only innovative but embodies a comprehensive approach by integrating hardware, software, and bioinformatics tools in one package.

A Unique Value Proposition

So what makes Inscripta special? It is the unique fusion of advanced CRISPR-based technology with a full-stack platform. Our Onyx™ platform revolutionizes genetic engineering with its automation capabilities, making gene-editing experiments easier and more affordable than ever. As a result, researchers can now explore larger variants, more complex genetic traits, and run more iterations with reduced effort and cost. Mark Schena, president of Illumina, said, “Inscripta has transformed the landscape of genetic editing with their precision tools and streamlined automation.” Illumina, a pioneer in genomic sequencing, echoed what numerous collaborators and customers found compelling: Inscripta’s capability to significantly enhance the scope and speed of genomic research.

The Onyx™ Platform: A Game Changer

The Onyx™ platform is the embodiment of Inscripta’s technological prowess. With a fully automated benchtop design, users can quickly design and implement new genetic editing tools. It includes consumables like reagents and technical support, adding continuous revenue streams post-initial sales. According to Grand View Research, "The global CRISPR and Cas genes market size was valued at $1.65 billion in 2020 and is expected to grow at a CAGR of 21.7% from 2021 to 2028, presenting a massive opportunity for Inscripta's pioneering solutions." The platform’s MAD7 enzyme, a proprietary single-protein CRISPR nuclease, provides improved efficiency and specificity for gene editing applications. This enzyme is unique in its class and has gained significant traction in both academic and industrial settings. Additionally, our Onyx™ kits priced at $1,000 per kit for industry-wide applications offer a cost-effective way for researchers to conduct precise, scalable experiments.

Driving Customer Relationships

At Inscripta, customer relationships are rooted in shared success and innovation. The consumables website allows users to select the reagents and protocols needed for specific experiments, while our software tools facilitate the management and analysis of data from gene-editing experiments. By not offering gene-editing services directly but empowering users to develop their own systems, we foster a culture of independence and creativity among our clients. To mention one of our key business relationships, Andreessen Horowitz Ventures, a reputable venture capital firm, has shown tremendous support towards our goals and innovation-driven strategies. Their backing underscores the capability of our technologies to lead the next generation of life sciences advancements.

Monetizing Innovation and Driving Growth

Inscripta’s business model stands on three major pillars: the sale of the Onyx™ platform, consumables, and associated services, and our focus on research and development leading to future product innovations. Through strategic partnerships and collaborative ventures, we extend our revenue streams through licensing and bundled technology solutions. As reported by the HBR, "The ability to derive continuous revenue from consumables and technical support illustrates Inscripta’s robust, sustainable business model." Through ongoing investments in R&D, Inscripta continually aims to develop new products and services, leveraging our intellectual property to its maximum potential. This ongoing innovation serves as a feeder for our revenue streams, keeping our business agile and market-relevant.

Social and Operational Impact

Beyond operational success, Inscripta's impact on society cannot be overstated. The capabilities embedded in our Onyx™ platform extend far beyond academic research, saving time and simplifying complex tasks—from addressing genetic diseases to contributing to food security efforts. Our role in these areas provides hope and wellness, underscoring our commitment to not just technological but also societal advancement. Dr. Jennifer Doudna, co-inventor of CRISPR technology, noted, "Platforms like Inscripta’s Onyx™ are vital in making scientific advancements more accessible, allowing the collective capabilities of scientific communities to tackle global challenges head-on."

Conclusion

Inscripta's journey from a visionary idea to a transformative force in genetic engineering illustrates the power of innovation, collaboration, and an unwavering commitment to democratizing science. By continuously evolving and scaling our technologies, we aim to unlock new potentials in genome engineering. We invite you to join us as we continue to push the boundaries of what's possible, creating a future where the limits of genetic science are only defined by the imagination of our scientific community. For more information, visit our website at https://www.inscripta.com/.